46K Stock Chart & Stats
€74.50
€0.00(0.00%)
At close: 4:00 PM EDT
€74.50
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€65.50 - €89.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€875.01M
Enterprise Value€1.05B
Total Cash (Recent Filing)€63.29M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)40.6
Beta0.26
Next Earnings
Feb 04, 2027EPS Estimate
0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.89
Shares Outstanding12,786,991
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio3.34
Price to Book (P/B)13.08
Price to Sales (P/S)14.77
P/FCF Ratio72.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€107.09Price Target Upside43.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.89
Revenue Forecast (FY)€82.22M
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained gross margins near 75–77% and a TTM net margin of roughly 26.8% indicate strong product economics and pricing power. These margins provide substantial capacity to fund research, sales expansion and service infrastructure while absorbing moderate cost or mix pressure.
Debt-Free Balance SheetAn effectively debt-free balance sheet materially reduces financial risk and interest burden, preserving flexibility through changing demand conditions. Rising equity and strong returns on equity also indicate that IRMD is generating attractive business returns without relying on leverage to amplify results.
3870 Replacement OpportunityThe installed base of older pumps creates a multi-year replacement opportunity for the higher-ASP 3870 platform. Quad-stack adoption can expand pump channels per MRI, while the identified replacement pool supports a durable growth runway beyond individual quarterly orders.
Bears Say
Reduced 2026 GuidanceThe reduced full-year outlook signals that execution or timing has been weaker than previously expected, lowering near-term earnings visibility. Repeated guidance pressure could constrain confidence in the growth trajectory and make the company more dependent on successful 3870 ramp execution.
Production Ramp ExecutionThe need to throttle production highlights execution risk as IRMD scales its newest platform. Protecting quality is strategically appropriate, but slower output can defer revenue, limit customer fulfillment and delay operating leverage while the manufacturing team continues up the learning curve.
Delayed Disposable Pull-ThroughThe expected recurring-revenue benefit from the 3870 installed base has not yet materially appeared, weakening the near-term monetization of new pump placements. If customer in-servicing and utilization take longer, consumables growth and the platform’s lifetime revenue potential could be delayed.
Iradimed News
46K FAQ
What was Iradimed Corp’s price range in the past 12 months?
Iradimed Corp lowest stock price was €65.50 and its highest was €89.50 in the past 12 months.
What is Iradimed Corp’s market cap?
Iradimed Corp’s market cap is €875.01M.
When is Iradimed Corp’s upcoming earnings report date?
Iradimed Corp’s upcoming earnings report date is Feb 04, 2027 which is in 95 days.
How were Iradimed Corp’s earnings last quarter?
Iradimed Corp released its earnings results on Oct 30, 2026. The company reported €0.491 earnings per share for the quarter.
Is Iradimed Corp overvalued?
According to Wall Street analysts Iradimed Corp’s price is currently Undervalued.
Does Iradimed Corp pay dividends?
Iradimed Corp does not currently pay dividends.
What is Iradimed Corp’s EPS estimate?
Iradimed Corp’s EPS estimate is 0.54.
How many shares outstanding does Iradimed Corp have?
Iradimed Corp has 12,786,991 shares outstanding.
What happened to Iradimed Corp’s price movement after its last earnings report?
Iradimed Corp reported an EPS of €0.491 in its last earnings report. Following the earnings report the stock price went up 2.013%.
Which hedge fund is a major shareholder of Iradimed Corp?
Currently, no hedge funds are holding shares in DE:46K
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iradimed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€107.09 (43.74% Upside)
€107.09 (43.74% Upside)
Blogger Sentiment
Bearish
DE:46K Sentiment 100%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth €110.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.72%
12-Months-Change
Fundamentals
Return on Equity
23.90%
Trailing 12-Months
Asset Growth
5.53%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Iradimed Corp
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
46K Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive, supported by record revenue and bookings, rapid adoption of the 3870 pump, strong monitor performance, improving manufacturing efficiencies, robust cash generation and an optimistic 2027 growth outlook. The main challenges were the reduced full-year guidance, the need to moderate the production ramp to protect quality, remaining 3870 production inefficiencies, higher taxes and expenses, and the fact that 3870 disposable pull-through has not yet begun materially.View all DE:46K earnings summaries46K Stock 12 Month Forecast
Average Price Target
€107.09
▲(43.74% Upside)
Technical Analysis
InfuSystem Holdings
―
Koninklijke Philips
―
Medtronic
―
LivaNova
―
GE Healthcare Technologies Inc
―